Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other financing activities (2020 - 2023)

10x Genomics' Other financing activities history spans 4 years, with the latest figure at $5.8 million for Q1 2023.

  • On a quarterly basis, Other financing activities rose 7.49% to $5.8 million in Q1 2023 year-over-year; TTM through Dec 2023 was $5.8 million, a 7.49% increase, with the full-year FY2023 number at $5.8 million, up 7.49% from a year prior.
  • Other financing activities hit $5.8 million in Q1 2023 for 10x Genomics, up from $5.4 million in the prior quarter.
  • Over the last five years, Other financing activities for TXG hit a ceiling of $5.8 million in Q1 2020 and a floor of $2000.0 in Q4 2020.
  • Historically, Other financing activities has averaged $4.4 million across 4 years, with a median of $5.4 million in 2022.
  • Biggest five-year swings in Other financing activities: decreased 13.99% in 2021 and later grew 7.58% in 2022.
  • Tracing TXG's Other financing activities over 4 years: stood at $2000.0 in 2020, then soared by 251300.0% to $5.0 million in 2021, then rose by 7.58% to $5.4 million in 2022, then rose by 7.49% to $5.8 million in 2023.
  • Business Quant data shows Other financing activities for TXG at $5.8 million in Q1 2023, $5.4 million in Q1 2022, and $5.0 million in Q1 2021.